Skip to main content
. 2020 Dec 28;110(1):123–131. doi: 10.1002/cpt.2127

Figure 3.

Figure 3

Time from the first description of an ADR in the SmPC of any of the TNF‐α inhibitors to the first description of the same ADR in the SmPC of a second TNF‐α inhibitor. ADR, adverse drug reactions; SmPC, summary of product characteristic. [Colour figure can be viewed at wileyonlinelibrary.com]